drugset / Trial / NCT04405375
GPED Regimen for Relapsed/Refractory or Advanced ENKTCL
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in the treatment of Relapsed/Refractory or advanced NK/T-cell lymphoma patients (ENKTCL).
Timeline
- Start
- 2020-03-21
- Primary completion
- 2023-04-30
- Completion
- 2023-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 20 mg | — |
| Subject | Etoposide | Small molecule | 75 mg/m2 | — |
| Subject | Gemcitabine | Small molecule | 1250 mg/m2 | — |
| Subject | Pegaspargase | Protein / enzyme biologic | 2500 unknown | — |